Core Insights - Immuneering Corporation is focused on developing Deep Cyclic Inhibitors, specifically atebimetinib, to improve overall survival in cancer patients by shrinking tumors durably and minimizing resistance [1][4] - The company will present findings at the AACR Annual Meeting, highlighting atebimetinib's ability to mitigate resistance mechanisms in RAS-mutant tumors [2][3] Company Overview - Immuneering is a late-stage clinical oncology company dedicated to enhancing the quality of life and survival rates for cancer patients [4] - The lead product candidate, atebimetinib, is an oral, once-daily medication targeting MEK, aimed at treating various cancer types, including pancreatic cancer [4] - The company plans to initiate a pivotal Phase 3 trial, MAPKeeper 301, in mid-2026, evaluating atebimetinib in combination with chemotherapy for first-line pancreatic cancer patients [4] Research Presentation Details - The poster presentation titled "Atebimetinib's Deep Cyclic Inhibition of MEK Constrains MAPK-Axis Adaptive and Acquired Alterations in Patients with RAS-Mutant Tumors" will take place on April 20, 2026, from 9:00 AM to 12:00 PM ET [3] - The analysis will include data from at least 64 patients with RAS-mutant solid tumors, demonstrating the potential of Deep Cyclic Inhibitors to provide sustained clinical benefits [2][3]

Core Insights - Immuneering Corporation reported a 64% overall survival rate at 12 months for first-line pancreatic cancer patients treated with atebimetinib + mGnP, significantly higher than the standard of care benchmark of 35% [1][2][3] - The company is on track to initiate the pivotal Phase 3 MAPKeeper 301 trial in mid-2026, following alignment with the FDA and EMA on trial design [1][3] - Immuneering ended 2025 with $217 million in cash and equivalents, providing a financial runway into 2029 [1][5] Clinical Developments - The ongoing Phase 2a trial of atebimetinib + mGnP showed a median follow-up of 13.4 months with a favorable safety profile, where only neutropenia and anemia were observed at grade 3 or higher in over 10% of patients [3] - The company plans to begin dosing in a Phase 2 trial of atebimetinib + Libtayo for first-line RAS-mutant non-small cell lung cancer in the second half of 2026 [1][3] Financial Performance - For Q4 2025, research and development expenses were $9.3 million, down from $14.9 million in Q4 2024, while full-year R&D expenses decreased to $42 million from $48 million [8] - General and administrative expenses for Q4 2025 increased to $4.5 million from $3.7 million in Q4 2024, with full-year G&A expenses rising to $17.3 million from $16.1 million [8] - The net loss for Q4 2025 was $11.6 million, or $0.18 per share, compared to a net loss of $18.1 million, or $0.58 per share, in Q4 2024 [8] Strategic Positioning - Immuneering's lead product candidate, atebimetinib, is a Deep Cyclic Inhibitor targeting MEK, designed to improve survival across various cancer types, particularly those driven by the MAPK pathway [6][9] - The company has a solid pipeline and is well-positioned to advance its mission of improving patient outcomes in oncology [2][9]

Core Viewpoint - Immuneering Corporation is a late-stage clinical oncology company focused on developing innovative cancer treatments aimed at improving patient survival and quality of life [2] Company Overview - Immuneering is developing a new category of cancer medicines called Deep Cyclic Inhibitors, which aim to enhance overall survival through three mechanisms: durable tumor shrinkage with reduced resistance, counteracting cachexia to preserve body mass, and minimizing side effects to improve performance status and combinability [2] - The lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, targeting various cancer indications, particularly MAPK pathway-driven tumors like pancreatic cancer [2] - The company plans to initiate dosing for the MAPKeeper 301 trial in mid-2026, a pivotal Phase 3 study evaluating atebimetinib in combination with chemotherapy for first-line pancreatic cancer patients [2] Upcoming Events - Immuneering's management will present at the Leerink Global Healthcare Conference in Miami, Florida, from March 9-11, 2026, with CEO Ben Zeskind discussing the company's pipeline, platform, and business strategy [1]

Summary of Immuneering's Conference Call Company Overview - **Company**: Immuneering - **Focus**: Development of atebimetinib, a novel oral drug candidate aimed at improving survival in first-line pancreatic cancer and other cancers Key Points Industry and Product - **Industry**: Biopharmaceuticals, specifically oncology - **Product**: Atebimetinib, categorized as a Deep Cyclic Inhibitor, designed to improve overall survival through three mechanisms: tumor shrinkage, body mass preservation, and side effect minimization [2][28] Clinical Data and Comparisons - **Survival Rates**: Reported 64% overall survival at 12 months in Phase 2a study, compared to a 35% benchmark for standard care (gemcitabine/nab-paclitaxel) [2][3][10] - **Disease Control Rate**: 81% in patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel, significantly higher than the 48% benchmark for standard care [6][17] - **Progression-Free Survival**: 8.5 months, compared to 5.5 months for standard care [16] - **Overall Response Rate**: 39%, higher than the 23% benchmark from standard care [16] Mechanisms of Action - **Three Mechanisms**: 1. **Tumor Shrinkage**: Effective in both RAS and RAF-driven tumors 2. **Body Mass Preservation**: 84% of patients maintained or gained weight, counteracting cachexia [6][8] 3. **Minimizing Side Effects**: Only two categories of Grade 3 or higher adverse events (neutropenia and anemia) seen in over 10% of patients [18][19] Future Studies and Trials - **Phase 3 Study**: MAPKeeper 301, a global randomized pivotal trial, will compare atebimetinib plus modified gemcitabine/nab-paclitaxel against standard care, with overall survival as the primary endpoint [3][27] - **Patient Enrollment**: Expanded cohort of over 50 patients expected to report data in the first half of 2026 [21][22] Regulatory and Market Position - **Regulatory Alignment**: Fully aligned with FDA and EMA for the Phase 3 study [3][29] - **Market Potential**: Targeting a broad range of RAS, RAF, and other MAPK-driven cancers, which account for about half of all tumors [4][30] Key Opinion Leader (KOL) Feedback - KOLs express excitement about the triple mechanism of action, emphasizing its potential to enhance patient quality of life and survival [33][36] Conclusion - Immuneering aims to establish atebimetinib as the new standard of care in first-line pancreatic cancer, leveraging its unique mechanisms to improve patient outcomes and quality of life [46][47]

Core Insights - Immuneering Corporation is set to provide an update on the 12-month overall survival data from its ongoing Phase 2a clinical trial of atebimetinib combined with modified Gemcitabine/nab-paclitaxel (mGnP) for first-line pancreatic cancer patients on January 7, 2026 [1][2] Company Overview - Immuneering Corporation is a late-stage clinical oncology company focused on improving the lives of cancer patients through innovative treatments [3] - The company is developing a new category of cancer medicines known as Deep Cyclic Inhibitors, with its lead product candidate, atebimetinib, being an oral, once-daily treatment targeting MEK [3] - Atebimetinib is designed to enhance durability and tolerability across various cancer types, particularly MAPK pathway-driven tumors like pancreatic cancer [3] - A Phase 3 trial for atebimetinib in first-line pancreatic cancer is expected to begin dosing in mid-2026 [3]

Core Insights - Immuneering Corporation is on track to initiate a global Phase 3 registrational trial for atebimetinib in first-line pancreatic cancer patients by mid-2026, evaluating its efficacy in combination with modified gemcitabine and nab-paclitaxel [1][4] Regulatory Interactions - The company has completed End-of-Phase 2 interactions with the FDA and received scientific advice from the EMA, achieving alignment on key elements of the proposed Phase 3 trial [2][5] - Feedback from both regulatory agencies supports the trial design and the primary endpoint of overall survival [3][5] Trial Design and Objectives - The MAPKeeper 301 trial will enroll approximately 510 patients and will compare atebimetinib (320 mg QD) in combination with modified gemcitabine and nab-paclitaxel (mGnP) against standard care gemcitabine and nab-paclitaxel (GnP) [3][4] - Secondary endpoints include progression-free survival, overall response rate, disease control rate, and quality of life measurements [3] Financial Outlook - The company expects to have sufficient cash and cash equivalents to fund operations into 2029 based on current operating plans [4] Industry Context - There is an urgent need for new therapies for pancreatic cancer, and the Phase 2a data for atebimetinib combined with chemotherapy shows promising signals [5]

Core Viewpoint - Immuneering Corporation is set to be added to the Nasdaq Biotechnology Index, effective prior to market open on December 22, 2025, highlighting its growing recognition in the biotechnology sector [1]. Company Overview - Immuneering Corporation is a late-stage clinical oncology company focused on developing innovative cancer treatments, specifically a new category of medicines known as Deep Cyclic Inhibitors [3]. - The lead product candidate, atebimetinib, is an oral medication designed to improve durability and tolerability for various cancer types, including pancreatic cancer, and is expected to enter a Phase 3 trial in mid-2026 [3]. Nasdaq Biotechnology Index (NBI) Details - The NBI tracks the performance of biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market, with specific eligibility requirements such as minimum market capitalization and average daily trading volume [2]. - The index is evaluated annually in December and employs a modified capitalization-weighted methodology for its calculations [2].

Core Insights - Immuneering Corporation reported an extraordinary 86% overall survival rate at 9 months for first-line pancreatic cancer patients treated with atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) [1][3] - The company raised a total of $225 million in financing, which includes a $25 million private placement with Sanofi, extending its cash runway into 2029 [1][2][3] - Immuneering received a U.S. composition of matter patent for atebimetinib, expected to provide exclusivity until 2042 [1][5] Clinical Developments - The Phase 2a trial of atebimetinib + mGnP showed a favorable tolerability profile with only two Grade 3 adverse events (neutropenia and anemia) observed in over 10% of patients [3] - New case studies highlighted patients achieving significant responses, including one with a complete response and another who could proceed to radiation and surgery with curative intent [4][5] - Immuneering plans to report updated survival data in the first half of 2026 and begin dosing patients in a pivotal Phase 3 trial by mid-2026 [6][8] Financial Performance - As of September 30, 2025, the company reported cash and cash equivalents of $227.6 million, a significant increase from $36.1 million at the end of 2024 [8] - Research and development expenses for Q3 2025 were $10.9 million, slightly down from $11.3 million in Q3 2024, while general and administrative expenses increased to $4.5 million from $4.0 million [9][10] - The net loss for Q3 2025 was $15.0 million, or $0.38 per share, compared to a net loss of $14.6 million, or $0.49 per share, in Q3 2024 [11][20] Future Milestones - Near-term milestones include receiving regulatory feedback and preparing to begin dosing patients in the pivotal trial of atebimetinib + mGnP [6] - The company anticipates reporting updated circulating tumor DNA data at a major scientific meeting in Q2 2026 [6] - Immuneering is also planning to dose the first patient in a trial of atebimetinib in combination with Libtayo for non-small cell lung cancer in the second half of 2026 [7]

Core Insights - Immuneering Corporation will report its third quarter 2025 financial results and share case studies from a Phase 2a study of atebimetinib in combination with FOLFIRINOX for first-line pancreatic cancer patients on November 12, 2025 [1] Company Overview - Immuneering is a clinical-stage oncology company focused on developing a new category of cancer medicines known as Deep Cyclic Inhibitors [3] - The lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK aimed at improving durability and tolerability for MAPK pathway-driven tumors, including pancreatic cancers [3] - Currently, atebimetinib is in a Phase 2a trial targeting advanced solid tumors, including pancreatic cancer [3]

Core Insights - Immuneering Corporation announced a conference call to discuss updated overall survival and safety data for first-line pancreatic cancer patients treated with atebimetinib + mGnP, with a median follow-up of 9 months [1][2] Company Overview - Immuneering is a clinical-stage oncology company focused on developing Deep Cyclic Inhibitors, with its lead product candidate, atebimetinib, designed to improve durability and tolerability for MAPK pathway-driven tumors, including pancreatic cancer [4] - The company is currently conducting a Phase 2a trial for atebimetinib in patients with advanced solid tumors, including pancreatic cancer [4] Upcoming Events - The updated results will be highlighted in a poster presentation at the Pancreatic Cancer Action Network Scientific Summit 2025 and discussed during the conference call [2]